• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Fortrea Holdings Inc.

    5/12/25 9:50:19 PM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)


    Fortrea Holdings Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    34965K107

    (CUSIP Number)


    JEFFREY C. SMITH
    STARBOARD VALUE LP, 777 Third Avenue, 18th Floor
    New York, NY, 10017
    212-845-7977


    ANDREW FREEDMAN, ESQ.
    OLSHAN FROME WOLOSKY LLP, 1325 Avenue of the Americas
    New York, NY, 10019
    212-451-2300


    MEAGAN REDA, ESQ.
    OLSHAN FROME WOLOSKY LLP, 1325 Avenue of the Americas
    New York, NY, 10019
    212-451-2300

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/08/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    STARBOARD VALUE & OPPORTUNITY MASTER FUND LTD
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,607,516.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    1,607,516.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    1,607,516.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.8 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    STARBOARD VALUE & OPPORTUNITY S LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    204,115.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    204,115.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    204,115.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.2 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value & Opportunity C LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value R LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value & Opportunity Master Fund L LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    85,307.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    85,307.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    85,307.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value L LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    85,307.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    85,307.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    85,307.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value R GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    85,307.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    85,307.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    85,307.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard X Master Fund Ltd
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    502,805.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    502,805.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    502,805.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.6 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Value GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Principal Co LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Starboard Principal Co GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,716,421.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,716,421.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Smith Jeffrey C
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,716,421.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,716,421.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    34965K107


    1 Name of reporting person

    Feld Peter A
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,716,421.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,716,421.00
    11Aggregate amount beneficially owned by each reporting person

    2,716,421.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.001 par value per share
    (b)Name of Issuer:

    Fortrea Holdings Inc.
    (c)Address of Issuer's Principal Executive Offices:

    8 MOORE DRIVE, DURHAM, NORTH CAROLINA , 27709.
    Item 1 Comment:
    The following constitutes Amendment No. 5 to the Schedule 13D filed by the undersigned ("Amendment No. 5"). This Amendment No. 5 amends the Schedule 13D as specifically set forth herein. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings given to them in the Schedule 13D.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 is hereby amended and restated to read as follows: The securities of the Issuer purchased by each of Starboard V&O Fund, Starboard S LLC, Starboard L Master, Starboard X Master and held in the Starboard Value LP Account were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted. The aggregate purchase price of the 1,607,516 Shares beneficially owned by Starboard V&O Fund is approximately $34,287,438, excluding brokerage commissions. The aggregate purchase price of the 204,115 Shares beneficially owned by Starboard S LLC is approximately $4,526,082, excluding brokerage commissions. The aggregate purchase price of the 85,307 Shares beneficially owned by Starboard L Master is approximately $1,927,093, excluding brokerage commissions. The aggregate purchase price of the 502,805 Shares beneficially owned by Starboard X Master is approximately $11,104,641, excluding brokerage commissions. The aggregate purchase price of the 316,678 Shares held in the Starboard Value LP Account is approximately $6,132,635, excluding brokerage commissions.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) is hereby amended and restated to read as follows: The percentages used in this Schedule 13D are based upon 90,500,000 Shares outstanding, as of May 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2025. See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Shares and percentage of the Shares beneficially owned by each of the Reporting Persons. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.
    (b)
    Item 5(b) is hereby amended and restated to read as follows: See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and the sole or shared power to dispose or to direct the disposition.
    (c)
    Item 5(c) is hereby amended and restated to read as follows: Information concerning transactions in the securities of the Issuer effected by the Reporting Persons during the past sixty days is set forth in Exhibit 1 attached hereto and is incorporated herein by reference. Except as otherwise noted, all of the transactions in the securities of the Issuer listed therein were effected in the open market through various brokerage entities.
    (e)
    Item 5(e) is hereby amended and restated to read as follows: As of May 8, 2025, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares of the Issuer.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 is hereby amended to add the following exhibit: 1 - Transactions in the Securities.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Starboard Value LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value GP LLC, its general partner
    Date:05/12/2025
     
    STARBOARD VALUE & OPPORTUNITY MASTER FUND LTD
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value LP, its investment manager
    Date:05/12/2025
     
    STARBOARD VALUE & OPPORTUNITY S LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value LP, its manager
    Date:05/12/2025
     
    Starboard Value & Opportunity C LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value R LP, its general partner
    Date:05/12/2025
     
    Starboard Value R LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value R GP LLC, its general partner
    Date:05/12/2025
     
    Starboard Value & Opportunity Master Fund L LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value L LP, its general partner
    Date:05/12/2025
     
    Starboard Value L LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value R GP LLC, its general partner
    Date:05/12/2025
     
    Starboard Value R GP LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory
    Date:05/12/2025
     
    Starboard X Master Fund Ltd
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Value LP, its investment manager
    Date:05/12/2025
     
    Starboard Value GP LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Principal Co LP, its member
    Date:05/12/2025
     
    Starboard Principal Co LP
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory of Starboard Principal Co GP LLC, its general partner
    Date:05/12/2025
     
    Starboard Principal Co GP LLC
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Authorized Signatory
    Date:05/12/2025
     
    Smith Jeffrey C
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Attorney-in-Fact for Jeffrey C. Smith
    Date:05/12/2025
     
    Feld Peter A
     
    Signature:/s/ Lindsey Cara
    Name/Title:Lindsey Cara, Attorney-in-Fact for Peter A. Feld
    Date:05/12/2025
    Get the next $FTRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    12/11/2025$21.00Neutral → Buy
    Citigroup
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    12/6/2024$28.00 → $25.00Outperform → Neutral
    Robert W. Baird
    9/25/2024$25.00 → $21.00Buy → Hold
    Jefferies
    8/8/2024$31.00 → $27.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units ("RSUs") on December 10, 2025, to two newly hired employees. The award consisted of 245,000 RSUs that vest in three equal annual installments starting December 10, 2026, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended a

    12/10/25 6:00:00 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery

    PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs and CROs can collaborate to deliver synchronized solutions that help to de-risk programs, streamline planning, expedite study setup and optimize cost-efficiency across the entire development lifecy

    12/4/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences

    DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December: Citi Global Healthcare Conference (Miami)Date:Tuesday, December 2, 2025Time:1:00 pm ETFormat:Fireside ChatWebcast:FTRE Citi webcast Evercore 8th Annual Healthcare Conference (Miami)Date:Wednesday, December 3, 2025Time:10:50 am ETFormat:Fireside ChatWebcast:FTRE Evercore webcast  The live webcasts and replay of the fireside chats will be accessib

    11/25/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sharbaugh William J

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    11/24/25 4:03:48 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Sharbaugh William J

    3 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/25/25 5:22:04 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Accounting Officer Parks Robert converted options into 24,934 shares and sold $73,013 worth of shares (7,338 units at $9.95), increasing direct ownership by 1,214% to 19,046 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/17/25 4:16:36 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by Citigroup with a new price target

    Citigroup upgraded Fortrea from Neutral to Buy and set a new price target of $21.00

    12/11/25 8:44:49 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Fortrea from Neutral to Outperform and set a new price target of $9.00

    8/4/25 8:16:07 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Truist initiated coverage on Fortrea with a new price target

    Truist initiated coverage of Fortrea with a rating of Hold and set a new price target of $7.00

    5/2/25 8:14:26 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    SEC Filings

    View All

    Fortrea Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    11/20/25 4:11:54 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.

    SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

    11/14/25 11:22:58 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Fortrea Holdings Inc.

    10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

    11/5/25 4:05:12 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Reports Third Quarter 2025 Results

    For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectivelyBook-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to a range of $175 million to $195 million DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported

    11/5/25 6:30:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call

    DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast

    10/15/25 7:00:24 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports Second Quarter 2025 Results

    For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 millionGAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $54.9 millionGAAP and adjusted net (loss) income per diluted share of $(4.14) and $0.19, respectivelyBook-to-bill ratio of 0.79x, resulting in 1.10x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,600 million to $2,700 million; affirming 2025 adjusted EBITDA guidance DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today rep

    8/6/25 6:30:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints William Sharbaugh to Board of Directors

    DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. "I'm delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations," said Anshul Thakral, CEO of Fortrea. "He is a highly respected leader, who understands our stakeholders a

    9/22/25 4:30:50 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care